Health

GSK plc has completed its acquisition of IDRx, Inc., aiming to advance treatments for gastrointestinal stromal tumours with the novel IDRX-42 inhibitor...
GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates...
GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns...
GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results...
GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe...
AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases...
GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates...
GSK's Shingrix aims for FDA-approved prefilled syringe to simplify shingles vaccination, enhancing convenience for healthcare providers...
GSK's ADC GSK5764227 gains FDA Breakthrough Therapy status for treating relapsed or refractory osteosarcoma, addressing critical unmet medical needs...
GSK's Nucala has been approved in China as an add-on treatment for CRSwNP, marking the first anti-IL-5 therapy for adults with this chronic condition...
AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials...
GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement...
GSK's Jemperli receives FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, expediting crucial development...
GSK announces FDA review of Nucala for COPD treatment following successful MATINEE study data, aiming to be the first approved monthly biologic...
AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...
GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage...
AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint...
AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients...
Haleon plc releases its Q3 2024 trading update, now available for review. Join the presentation on October 31 for in-depth analysis and insights...
Search

Funds

Financial Services

GSK plc has completed its acquisition of IDRx, Inc., aiming to advance treatments for gastrointestinal stromal tumours with the novel IDRX-42 inhibitor...
GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates...
GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns...
GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results...
GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe...
AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases...
GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates...
GSK's Shingrix aims for FDA-approved prefilled syringe to simplify shingles vaccination, enhancing convenience for healthcare providers...
GSK's ADC GSK5764227 gains FDA Breakthrough Therapy status for treating relapsed or refractory osteosarcoma, addressing critical unmet medical needs...
GSK's Nucala has been approved in China as an add-on treatment for CRSwNP, marking the first anti-IL-5 therapy for adults with this chronic condition...
AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials...
GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement...
GSK's Jemperli receives FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, expediting crucial development...
GSK announces FDA review of Nucala for COPD treatment following successful MATINEE study data, aiming to be the first approved monthly biologic...
AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...
GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage...
AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint...
AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients...
Haleon plc releases its Q3 2024 trading update, now available for review. Join the presentation on October 31 for in-depth analysis and insights...
Search

Funds

Health

FTSE 100

Funds